PCM
CNST

Peregrine Capital Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Peregrine Capital Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-277,419
Closed -$6.49M – 360
2021
Q1 		$6.49M Buy
+277,419
New +$8.4M 0.12% 253

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Peregrine Capital Management's CNST Position: Q2 2021 in Review

Peregrine Capital Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 277,419 shares — an estimated $6.49M sold.

Peregrine Capital Management first reported a position in CNST in Q1 2021 and held it in 1 quarter. The position peaked at $6.49M in Q1 2021. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Peregrine Capital Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Peregrine Capital Management sold 277,419 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $6.49M.
  • Peregrine Capital Management first reported a position in Constellation Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Peregrine Capital Management's Constellation Pharmaceuticals, Inc. position peaked at $6.49M in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Peregrine Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.